Background {#Sec1}
==========

Crohn\'s disease (CD) is a chronic relapsing inflammatory condition of the gastrointestinal tract that can result in lifelong ill health \[[@CR1]\]. Immunosuppressive drugs, including biologicals, are the standard of care for CD, but some patients do not respond or lose response to treatment \[[@CR2], [@CR3]\]. Therefore, alternative treatments for refractory CD remain an unmet need.

Hematopoietic stem cell transplantation (HSCT) might play a role in some of these treatment-resistant cases \[[@CR4]\]. Previous studies have indicated that allogeneic HSCT may reset the immune system at a genetic level \[[@CR5], [@CR6]\], and autologous HSCT eliminates aberrant clones by immunoablation and replacement with uncommitted stem cells (SCs), leading to de novo generation of an altered T-cell repertoire \[[@CR7]\]. Case reports and series describe long-term treatment-free disease regression with autologous \[[@CR8]--[@CR10]\] and allogeneic \[[@CR5], [@CR6]\] HSCT in some \[[@CR6], [@CR11], [@CR12]\] but not all patients \[[@CR8]--[@CR10]\] with CD. However, the recent Autologous Stem Cell Transplantation International Crohn Disease (ASTIC) trial \[[@CR13]\] failed to demonstrate a statistically significant improvement in sustained disease remission at 1-year of autologous HSCT compared with conventional therapy. These findings raise doubt about HSCT for patients with refractory CD.

Perianal fistulas are very common complications, appearing in 25% of CD patients. Of these, approximately half are complex. The only approved drug that has shown efficacy in a randomized clinical trial is infliximab \[[@CR14], [@CR15]\]. Few treatment options exist for drug treatment-refractory patients, and repeated surgical options are associated with a significant risk of permanent stoma. These findings emphasize the need for novel treatment options for treatment-refractory complex perianal fistulas in patients with CD. Initial clinical results \[[@CR16], [@CR17]\] suggested mesenchymal stem cells (MSCs) might have therapeutic potential in this setting.

Given the immunoregulatory potential of SCs, multiple studies have been conducted to assess the safety and efficacy of stem cell therapy (SCT) in CD. In this study, we perform a meta-analysis of feasibility and toxicity of SCT for the treatment of CD.

Methods {#Sec2}
=======

The study was performed following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines \[[@CR18]\].

Literature search {#Sec3}
-----------------

We identified relevant literature (published articles and abstracts) by performing a systematic search of three databases: PubMed, Cochrane Library CENTRAL, and Embase (initial search February 5, 2015; updated October 15, 2016). Keywords used were (all fields): ("inflammatory bowel disease" or "crohn's disease" or "crohn disease" or "enteritis") and ("stem cell\*" OR "precursor cell\*" OR "progenitor cell\*" OR "Stromal cell\*"), and any appropriate abbreviations. For PubMed, all relevant MeSH terms were used. The final queries were validated by manual review and matching results.

The conference proceeding abstracts for annual meetings of European (European Crohn's and Colitis Organisation congress) and American (Digestive Disease Week) Congresses were searched between 2002 and 2016.

Study selection {#Sec4}
---------------

We finally performed a manual selection of studies which satisfied the following criteria: (a) observational (prospective or post hoc analysis of prospectively obtained cohort) or interventional design (randomized or non-randomized); (b) established diagnosis of CD by accepted criteria not in clinical or endoscopic remission at study outset; and (c) clear definition of efficacy and adverse events (AEs). Studies with exclusively pediatric patients (\<15 years), a diagnosis of ulcerative colitis, indeterminate colitis, or an unclear diagnosis of CD and case reports were also excluded.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Eligible articles were reviewed in a blind manner by two different investigators (YQ and MYL), and the results of the primary research studies were abstracted onto specially designed data extraction forms. Disagreement in data extraction was resolved by consensus with MHC.

Assessment of the quality of randomized controlled trials (RCTs) and observational studies was performed using the Cochrane risk of bias tool \[[@CR19]\] and Newcastle Ottawa Quality Assessment Scale (NOS) \[[@CR20]\], respectively. For the NOS, studies scoring [\>]{.ul}7 (of 9) were considered high quality.

Outcomes assessed {#Sec6}
-----------------

The primary endpoint was clinical efficacy (e.g., clinical response or remission, fistula healing as defined by the primary study) of SCs for the treatment of patients with CD. Secondary outcomes were safety (e.g., AEs, severe AEs (SAEs)) and other measures of disease activity (endoscopic remission, clinical recurrence) of SCT for CD.

Data synthesis and analysis {#Sec7}
---------------------------

We calculated incidence estimates with the variance-stabilizing double arcsine transformation \[[@CR21]\] because the inverse variance weight in fixed-effects meta-analyses is suboptimum when dealing with binary data with low incidences. Additionally, the transformed incidences are weighted very slightly towards 50%, and studies with incidences of zero can thus be included in the analysis. We used the Wilson method \[[@CR22]\] to calculate 95% confidence intervals (CIs) around these estimates because the asymptotic method produces intervals which can extend below zero. Heterogeneity due to study variation was assessed using the χ^2^ test \[[@CR23], [@CR24]\], with a *P* value of \<0.10 being considered as statistically significant.

Publication bias {#Sec8}
----------------

Funnel-plot asymmetry as proposed by Egger et al. \[[@CR25]\] was used to investigate the possibility of publication bias.

The meta-analysis was performed using the metaprop command of the meta package in R (version 3.2.0) \[[@CR26]\] and Stata (version 12.1) with the commands metareg (for metaregression). All statistical tests were two-sided, and statistical significance was defined as a *P* value \<0.05.

Outcomes {#Sec9}
--------

The initial search strategy yielded 4828 abstracts for review, of which 108 were selected for detailed review. Seventy-one studies were excluded for being non-human or safety studies or studies with exclusively pediatric patients, or for having a diagnosis of UC or indeterminate colitis or mixed irritable bowel syndrome for which the CD data could not be separated. Sixteen studies were further excluded because they were case studies or duplicate studies (Fig. [1](#Fig1){ref-type="fig"}; Additional file [1](#MOESM1){ref-type="media"}: Table S1).Fig. 1Study selection

The main characteristics of the included 20 studies \[[@CR9], [@CR10], [@CR13], [@CR16], [@CR27]--[@CR42]\] are detailed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. The included two Park et al. studies \[[@CR32], [@CR37]\] and two Cho et al. studies \[[@CR33], [@CR38]\] were not duplicated. Among the included 20 studies, three \[[@CR9], [@CR10], [@CR13]\] were about the systemic infusion of hematopoietic stem cells, seven \[[@CR27], [@CR29]--[@CR31], [@CR36], [@CR39], [@CR40]\] the systemic infusion of bone marrow-derived MSCs (BMSCs), and ten \[[@CR16], [@CR28], [@CR32]--[@CR35], [@CR37], [@CR38], [@CR41], [@CR42]\] the local injection of MSCs; the numbers of transplanted SCs ranged from 10^7^ to 1.5 × 10^10^. All studies defined clinical or endoscopic response with the Crohn's Disease Activity Index (CDAI) and CD Endoscopic Index of Severity (CDEIS). All 15 observational studies were considered as high quality (scoring [\>]{.ul}7) using the NOS and the 2/6 RCTs \[[@CR13], [@CR27], [@CR28], [@CR37], [@CR39], [@CR42]\] had low risk of bias. Detailed quality assessments are provided in Additional file [2](#MOESM2){ref-type="media"}: Figure S1, Additional file [1](#MOESM1){ref-type="media"}: Table S1 and Additional file [3](#MOESM3){ref-type="media"}: Table S2.Table 1Characteristics of included studies evaluating the efficacy and safety of stem cell therapy for patients with Crohn's diseaseStudyNumber of subjectsSex (M:F)Age (years): mean (SD)Duration (years): mean (SD)Prior medications, n(%)Bowel surgeryConcomitant medicationsCDAI: mean (SD)DesignLocationIMBiologicalSteroidIMBiologicalSteroid5-ASABurt et al. 2010 \[[@CR9]\]2412:122710YYY71% (17/24)NNY-235Phase I/IIa open label, single armUSACassinotti et al. 2012 \[[@CR43]\]107:3\-\-\-\-\-\-\-\-\--Phase I/IIa open label, single armItalyHasselblatt et al. 2012 \[[@CR10]\]128:436.5 (range 24--50)12.7 (range 2--24)YYY8YYYY285 ± 79Phase I/IIa open label, single armGermanyHawkey et al. 2015 \[[@CR13]\]2311:13Median 34.114.9 (IQR,9.9-16.9)\--N2 (IQR,0.5--3.5)NNN-326 (range 251--414)RCT, multicenterEuropeanOnken et al. 2006 \[[@CR27]\]10\-\-\-\-\-\-\-\-\-\-\--Phase II, open label, double arm, randomizedUSADuijvestein et al. 2010 \[[@CR29]\]102:8Median 32.53 \~ 12YYY4YNYYMedian 299.5 (range 255--442)Phase I, open label, single armNetherlandsForbes et al. 2014 \[[@CR36]\]166:1021--55\--Y-3YNY-\>250Phase II, open label, single arm multicenterAustraliaLazebnik et al. 2010 \[[@CR30]\]50 (11 CD)\-\-\-\-\-\--NNY-261.5 ± 18.2 (range 206--298)Open label, double armRussiaDhere et al. 2016 \[[@CR40]\]126:618--52-YYN-NNN-\>220Phase IUSAGarcia-Olmo et al. 2005 \[[@CR16]\]53:235.1 ± 2.4-YYYYNNNN-Phase I, open label, single armSpainGarcia-Olmo et al. 2009 \[[@CR28]\]49 (14 CD)10:1442.64 ± 10.93-6 (25)N-Fistula:17 (71)\-\-\-\--Phase II, open label, double arm, randomizedSpainCiccocioppo et al. 2011 \[[@CR31]\]128:4Median 32-YYYYYNYY294 ± 49Open label, single armItalyPark et al. 2012 \[[@CR32]\]116:524.6\--5\-\-\-\-\-\--Phase I/IIa open label, single armKoreade la Portilla et al. 2013 \[[@CR34]\]2411:1336 ± 9\-\-\-\--YNYY-Phase I/IIa open label, single armSpainCho et al. 2013 \[[@CR33]\]104:626.5 ± 6\-\-\-\-\-\-\-\-\--Phase I, open label, single armKoreaLee et al. 2013 \[[@CR35]\]3322:1126.7 ± 5.654.6 ± 40.1 months\-\-\--41 (95.3)\-\-\--Phase II, open label, single armKoreaPark et al. 2014 \[[@CR37]\]6\-\-\-\-\-\-\-\-\-\-\--Multicenter, randomized phase I/IIaKoreaCho et al. 2015 \[[@CR38]\]4128:1326.2 ± 5.5\-\-\-\-\-\-\-\-\--f/u of phase IIKoreaMolendijk et al. 2015 \[[@CR39]\]21\-\-\-\-\-\-\-\-\-\-\--Double-blind RCTNetherlandsLightner et al. 2016 \[[@CR41]\]73:4314.5YYYY\-\-\-\--Phase IUSAPanés et al. 2016 \[[@CR42]\]21260:4739 ± 1312.1 ± 1089 (83%)83 (78%)6/103 (5%)-44 (41%)37 (35%)6/103 (5%)-88.7 ± 48.8Phase III double-blind RCT multicenterEuropean, Israel*Abbreviations*: *CD* Crohn's disease, *CDAI* Crohn Disease Activity Index, *N* no, *Y* yes, *5-ASA* 5-Aminosalicylic acid, *IM* immunomodulators Table 2Characteristics of included studies evaluating the efficacy and safety of stem cell therapy for patients with Crohn's diseaseStudyProcedureInfusionNumber of cellsOutcomeCriteria: clinical remissionMRIRemission/response/closure (number of patients, time of evaluation)SAEsInfectionsRecurrence (number of patients, time of evaluation)AutologousSourceBurt et al. 2010 \[[@CR9]\]YHSCsS2. 10E6/kgCDAI, CSICDAI \<150-Clinical: 24 (6--12 m)1 not related119% (12 m)CSI \<1237% (24 m)Asymptomatic with no IM43% (36 m)Cassinotti et al. 2012 \[[@CR43]\]YHSCsSUnknownCDAI\--Clinical: 10 (3 m)None-20% (12 m)Endoscopic: 5 (3 m)50% (24 m)Hasselblatt et al. 2012 \[[@CR10]\]YHSCsSUnknownCDAICDAI \<150-Clinical: 5 (6 m)4 related-7 (37.2 m)Endoscopic: 5 (6 m)Fever, renal failureHawkey et al. 2015 \[[@CR13]\]YHSCsS3 \~ 8.10E6/kgCDAISustained disease remission:-2/23 versus 1/22 (12 m)76 versus 38 related9 SAEs in 5 patients undergoing HSCT:-(ASTIC)1) CDAI \<150 for \>3 m10 versus 2 (1 year)3 EBV reactivation, 2 CMV reactivation,2) No active treatment in the last 3 m1 herpes zoster, 1 BK virus, 1 intestinal adenovirus, 1 VZV3) No mucosal erosion or ulceration in GI tract8 neutropenic sepsisOnken et al. 2006 \[[@CR27]\]NProchymal™SUnknownCDAI-Clinical: 9/3 (14 d)1 unrelatedNone-Duijvestein et al. 2010 \[[@CR29]\]YBMSCsS2 × 1/2.10E6/kgCDAI, CDEISRemission: CDAI \<150-Clinical: 3/0 (6 w)NoneNone-Response: a drop in CDAI \>70Endoscopic: 2/0 (6 w)Lazebnik et al. 2010 \[[@CR30]\]NBMSCsS150--200.10E8CDAI, RCAI, Mayo, and Gebs scales\--Clinical: 11/0 (4--8 m, CD)-None-39/0 (4--8 m, UC)Forbes et al. 2014 \[[@CR36]\]NBMSCsS4 × 2.10E6/kgCDAI, CDEISRemission: CDAI \<150-Clinical: 12/8 (42 d)1 unrelated1 gastroenteritis-Endoscopic improvement: CDEIS \<3 or a decrease by \>5Endoscopic: 7/0 (42 d)Dhere et al. 2016 \[[@CR40]\]YBMSCsS2/5/10.10E6/kgCDAIResponse: CDAI + CRP-Clinical: 5/- (2 w)71 acute appendicitis-2 related1 *C. difficile* colitisGarcia-Olmo et al. 2005 \[[@CR16]\]YASCsLUnknownFistula closure-N8 fistulas in 4: 2/6 (8 w)NoneNone-Garcia-Olmo et al. 2009 \[[@CR28]\]YASCs + Fg:25 (7 CD)L20/60.10E6Fistula closure-NASCs + Fg: -/1 (7 CD, 8 w)NonePerianal sepsis: ASC group (*n* = 3, 12%) versus Fg alone (*n* = 9, 36%) (*P* = 0.04).Group B: 3 (12 m)Fg:24 (7 CD)Fg: 2/5 (7 CD, 8 w)No data for CDCiccocioppo et al. 2011 \[[@CR31]\]YBM-MSCsL50.10E6Complete closureCDAI + PDAIY3/7 (12 m)NoneNoneNone (12 m)Park et al.2012 \[[@CR32]\]YASCs + FgL1 \~ 4.10E7Fistula healing-N-/9 (8 w)\-\--de la Portilla et al. 2013 \[[@CR34]\]NASCsL20/60.10E6Fistula closure-Y23 fistulas in 22: 5/18 (6 m)2Infections and infestations 9/7-Anal abscess 5/4Anal fistula infection 2/2Cho et al. 2013 \[[@CR33]\]YASCsL10/20/40.10E6Fistula healing-N1/3 (2 m)None3 enterocolitis3 (8 m)Lee et al. 2013 \[[@CR35]\]YASCsL30/60.10E6Fistula healing-N5/27 (2 m)NoneNo ASC-related AEs3 (12 m)1 grade 4 peritonitis caused by CDPark et al. 2014 \[[@CR37]\]NASCsL10/30.10E6Complete closure-N-/1 (8 w)\-\-\--/3 (8 m)Cho et al. 2015 \[[@CR38]\]YASCsL30/60.10E6Fistula healing-N28/35 (12 m)NoneNone3/26 (12 m)27/36 (24 m)4/24 (24 m)Molendijk et al. 2015 \[[@CR39]\]YBMSCs (*n* = 15)L10/30/90.10E6Fistula healing-Y8 versus 1 (week 6)NoneNone-Placebo7 versus 2(wk 12)(*n* = 6)9 versus 2 (week 24)Lightner et al. 2016 \[[@CR41]\]YASCsLUnknownFistula healing-Y6/6 (6 m)\-\--Panés et al. 2016 \[[@CR42]\]NASCs (Cx601)L120.10E6Combined remission-Y53/107 versus 36/105SAE: 18/103 versus 14/103Anal abscess (6 versus 9)-SalineSAE related: 5/103 versus 7/103Proctalgia (5 versus 9)*Abbreviations*: *ASC* adipose-derived MSC, *BMSC* bone marrow-derived MSC, *CD* Crohn's disease, *CDAI* Crohn Disease Activity Index, *CDEIS* CD Endoscopic Index of Severity, *CSI* Crohn Severity Index, *Fg* fibrin glue, *GI* gastrointestinal, *HSC* hematopoietic stem cell, *L* local, *m* month, *N* no, *S* systemic, *SAE* serious adverse event, *w* week, *Y* yes, *RCAI* Rahmilevich Clinical Activity Index, *PDAI* perianal disease activity index, *IM* immunomodulators, *CRP* C-reactive protein, *UC* ulcerative colits, *VZV* varicella-zoster virus

Efficacy of SCT as a systemic infusion for CD {#Sec10}
---------------------------------------------

### Clinical response {#Sec11}

Eleven studies \[[@CR16], [@CR27], [@CR29]--[@CR31], [@CR33]--[@CR36], [@CR40], [@CR41]\] reported raw data on clinical response of patients with SCT. Rates of clinical response ranged from 10 to 100%. The random-effects pooled rate of clinical response was 56% (95% CI 33--76, *n* = 150); heterogeneity was pronounced (χ^2^ = 1.88, *P* \< 0.001; *I* ^2^ = 78.6%; Fig. [2a](#Fig2){ref-type="fig"}). Subgroup analyses were performed to assess whether the source of the stem cells, i.e., HSCT or MSCT, and the method of SC infusion had substantial effects on the efficacy of SCs as well as decreased the high heterogeneity.Fig. 2Estimated incidence of **a** clinical response, **b** clinical remission, and **c** endoscopic remission among CD patients who received SCT. *ASC* adipose mesenchymal stem cell, *BMSC* bone marrow-derived mesenchymal stem cell

Six studies \[[@CR27], [@CR29]--[@CR31], [@CR36], [@CR40]\] reported raw data on the outcome of patients with bone marrow-derived MSC (BMSC) therapy. The pooled rate of clinical response was 59% (95% CI 34--80, *n* = 79) compared to 51% (95% CI 13--88, five studies \[[@CR16], [@CR33]--[@CR35], [@CR41]\], *n* = 71) for patients who had ASC infusion (Table [3](#Tab3){ref-type="table"}).Table 3Summary of subgroup analysis of stem cells for the treatment of patients with CDClinical responseClinical remissionFistula closureItemsnHeterogeneityES95% CInHeterogeneityES95% CInHeterogeneityES95% CI*I* ^*2*^*PI* ^*2*^*PI* ^*2*^*P*Overall1178.6%\<0.0010.56\[0.33--0.76\]868.5%0.0020.46\[0.25--0.69\]1259.9%0.0030.57\[0.44--0.69\]Source HSC0\-\-\--475.9%0.0060.73\[0.36--0.93\]280.8%0.0220.29\[0.03--0.85\] BMSC669.8%0.0050.59\[0.34--0.80\]460.1%0.0570.23\[0.07--0.54\]20.0%0.7400.60\[0.44--0.75\] ASC584.6%\<0.0010.51\[0.13--0.88\]0\-\-\--965.3%0.0030.62\[0.42--0.79\]Source Autologous749.6%0.0640.31\[0.17--0.49\]576.4%0.0020.61\[0.25--0.88\]959.5%0.0110.62\[0.44--0.77\] Allogeneic426.7%0.2510.86\[0.71--0.94\]356%0.1030.32\[0.11--0.62\]430.2%0.2310.47\[0.33--0.61\]Routine Systemic567.7%0.0010.66\[0.39--0.86\]868.5%0.0020.46\[0.25--0.69\]280.8%0.0230.29\[0.03--0.85\] Local681.0%\<0.0010.45\[0.16--0.79\]0\-\-\--1157.9%0.0020.60\[0.47--0.72\]*Abbreviations*: *ASC* adipose-derived mesenchymal stem cell, *BMSC* bone marrow-derived mesenchymal stem cell, *HSC* hematopoietic stem cell

Seven studies \[[@CR16], [@CR29], [@CR31], [@CR33], [@CR35], [@CR40], [@CR41]\] reported results in patients with autologous SCT. The pooled rate of clinical response was 31% (95% CI 17--49, *n* = 89) compared to 86% (95% CI 71--94, four studies \[[@CR27], [@CR30], [@CR34], [@CR36]\], *n* = 61) for patients who underwent allogeneic SCT (Table [3](#Tab3){ref-type="table"}).

The pooled rate of clinical response was 66% (95% CI 39--86, five studies \[[@CR27], [@CR29], [@CR30], [@CR36], [@CR40]\], *n* = 59) in patients who received systemic SCT compared to 45% (95% CI 16--79, six studies \[[@CR16], [@CR31], [@CR33]--[@CR35], [@CR41]\], *n* = 91) for patients with local SCT (Table [3](#Tab3){ref-type="table"}).

### Clinical remission {#Sec12}

Eight studies \[[@CR9], [@CR10], [@CR13], [@CR27], [@CR29], [@CR30], [@CR36], [@CR43]\] reported raw data on clinical remission (mainly defined as a CDAI \<150; Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}) of patients with SCT. A random-effects meta-analysis of all studies of SCT as systemic infusion showed that 46% (95% CI 25--69, *n* = 116) of patients achieved clinical remission after infusion of SCs (Fig. [2b](#Fig2){ref-type="fig"}). Heterogeneity was modest (χ^2^ = 1.11, *P* = 0.002; *I* ^2^ = 68.5%).

Four studies \[[@CR9], [@CR10], [@CR13], [@CR43]\] reported raw data on the outcome of patients with HSCT. The pooled rate of clinical remission was 73% (95% CI 36--93, *n* = 69) in patients who received HSCT compared to 23% (95% CI 7--54, four studies \[[@CR27], [@CR29], [@CR30], [@CR36]\], *n* = 47) of patients who received MSCT (Table [3](#Tab3){ref-type="table"}).

### Endoscopic remission {#Sec13}

Four studies \[[@CR10], [@CR29], [@CR36], [@CR43]\] reported raw data on the endoscopic remission of patients with SCT. Rates of endoscopic remission ranged from 0--50% (Fig. [2c](#Fig2){ref-type="fig"}). The random-effects pooled rate of endoscopic remission was 15% (95% CI 0--50, *n* = 48); heterogeneity was pronounced (χ^2^ = 0.42, *P* \< 0.001; *I* ^2^ = 83.9%).

### Efficacy of SCT for perianal CD (local therapy) {#Sec14}

Thirteen studies \[[@CR8], [@CR10], [@CR16], [@CR28], [@CR31]--[@CR35], [@CR37], [@CR39], [@CR41], [@CR42]\] reported raw data on the efficacy of SCT for perianal CD of patients with SC injection. A random-effects meta-analysis of all perianal CD studies showed that 57% (95% CI 44%--69%, *n* = 251) of patients had healed fistula after local MSC injection (Fig. [3a](#Fig3){ref-type="fig"}) with mild heterogeneity (χ^2^ = 0.47, *P* = 0.003; *I* ^2^ = 59.9%).Fig. 3Forest plot of **a** studies evaluating healing of perianal fistulas (perianal CD) with SCT. **b** Comparison of SCT versus control. *ASC* adipose mesenchymal stem cell, *BMSC* bone marrow-derived mesenchymal stem cell, *HSCT* hematopoietic stem cell

Nine studies \[[@CR16], [@CR28], [@CR32]--[@CR35], [@CR37], [@CR41], [@CR42]\] reported raw data on the outcome of patients who received ASC injection. The random-effects pooled rate of fistula healing was 60% (95% CI 44--75, *n* = 203) compared to 29% (95% CI 3--85, two studies \[[@CR8], [@CR10]\], *n* = 24) for patients who received HSCT and 62% (95% CI 42--79, two studies \[[@CR31], [@CR39]\], *n* = 24) for patients who received BMSC (Table [3](#Tab3){ref-type="table"}).

Nine studies \[[@CR8], [@CR10], [@CR16], [@CR31]--[@CR33], [@CR35], [@CR39], [@CR41]\] reported results in patients with autologous SCT with a pooled rate of fistula healing of 62% (95% CI 44--77, *n* = 113) compared to 47% (95% CI 33--61, four studies \[[@CR28], [@CR34], [@CR37], [@CR42]\], *n* = 138) for patients who underwent allogeneic SCT (Table [3](#Tab3){ref-type="table"}). No heterogeneity existed between the studies.

The pooled rate of fistula healing was 29% (95% CI 3--85, two studies \[[@CR8], [@CR10]\], *n* = 24) for patients who received systemic SCT compared to 60% (95% CI 47--72, 11 studies \[[@CR16], [@CR28], [@CR31]--[@CR35], [@CR37], [@CR39], [@CR41], [@CR42]\], *n* = 227) for patients who received local SCT (Table [3](#Tab3){ref-type="table"}).

### Comparison of SC versus control {#Sec15}

Among the 13 studies, five \[[@CR27], [@CR28], [@CR37], [@CR39], [@CR42]\] were double-armed; both Onken et al. \[[@CR27]\] and Park et al. \[[@CR37]\] compared two different doses of SCs. Thus, three studies \[[@CR28], [@CR39], [@CR42]\] were pooled, yielding an odds ratio (OR) of 3.83 (95% CI 1.06--13.86, *n* = 121, *P =* 0.04) for achieving fistula healing in patients who received SCT versus control (Fig. [3b](#Fig3){ref-type="fig"}). Heterogeneity was modest (χ^2^ = 6.37, *P* = 0.04; *I* ^2^ = 69%).

### Recurrence {#Sec16}

Six studies \[[@CR9], [@CR10], [@CR31], [@CR33], [@CR35], [@CR43]\] reported raw data on recurrence for patients with SCT. Rates of recurrence ranged from 0 to 58% with a follow-up of \>12 months (Fig. [4](#Fig4){ref-type="fig"}). The random-effects pooled rate of recurrence was 16% (95% CI 4--34, *n* = 101); heterogeneity was pronounced (χ^2^ = 0.15, *P* = 0.004; *I* ^2^ = 71.3%).Fig. 4Estimated incidence of clinical recurrence among CD patients who received SCT

Three studies \[[@CR9], [@CR10], [@CR43]\] reported raw data on the outcome of patients with HSCT. The pooled rate of clinical remission was 25% (95% CI 6--64, *n* = 46) for patients who received HSCT compared to 17% (95% CI 5--45, four studies \[[@CR33], [@CR35]\], *n* = 43) for patients who received ASCs and 4% (95% CI 0--40, four studies \[[@CR31]\], *n* = 12) for patients who received BMSCs.

### Safety profile {#Sec17}

Overall, the included studies demonstrate that administration of SCs could lead to minor adverse reactions like perianal sepsis; however, serious adverse reactions leading to hospitalization are less common and perhaps related to underlying CD activity (Table [2](#Tab2){ref-type="table"}). Eighteen \[[@CR9], [@CR10], [@CR13], [@CR16], [@CR17], [@CR27], [@CR29], [@CR31], [@CR33]--[@CR42]\] of 20 studies reported raw data on severe adverse events (SAEs) of patients with SCT. Rates of SAE ranged from 0--83%. The random-effects pooled rate of SAEs was 12% (95% CI 6--23, *n* = 378); heterogeneity was modest (χ^2^ = 1.68, *P* \< 0.001; *I* ^2^ = 73.8%; Fig. [5](#Fig5){ref-type="fig"}). The random-effects pooled rate of SAEs related to SCT was 8% (95% CI 3--18, *n* = 378); heterogeneity was modest (*P* \< 0.001; *I* ^2^ = 74.2.6%).Fig. 5Estimated incidence of SAEs among CD patients who received SCT

### Publication bias and heterogeneity {#Sec18}

A funnel plot generated for the primary outcome suggested no publication bias (Fig. [6](#Fig6){ref-type="fig"}), as did an Egger test for fistula healing (t = −0.97, *P* = 0.36), but not for clinical response (t = −4.91, *P* = 0.003).Fig. 6Begg's funnel plot for publication bias for evaluating clinical response. *S.e.* standard error

Discussion {#Sec19}
==========

Our meta-analysis suggests that SCT has good therapeutic potential with relatively low risk of AEs for patients with CD, particularly for those who have perianal disease and are treated with local therapy.

MSCs have regenerative and immunomodulatory properties which lead to reduction of inflammation and healing of affected intestinal tissue. A previous meta-analysis showed that 40.5% (95% CI 7.5--78.5) of patients achieved remission after systemic infusion of MSCs \[[@CR44]\] compared to 23% (95% CI 7--54) in our study. Autologous and allogeneic MSC administration are both being evaluated; their unique cell surface HLA characteristics allow for therapy with unrelated donor cells without increasing the risk of rejection by the host. According to our study, the pooled rate of clinical remission was 32% (95% CI 11--62) for patients who underwent allogeneic MSCT compared to 61% (95% CI 25--88) for patients who underwent autologous SCT (Table [3](#Tab3){ref-type="table"}). However, patients who underwent allogeneic MSCT had a relatively higher pooled rate of clinical response compared with patients who underwent autologous SCT (86 versus 31%). Whether allogeneic MSCT has a superior therapeutic efficacy for CD warrants further study.

When considering HSCT, the question remains whether its risk to benefit ratio justifies it. Observations of case reports published to date suggest that sustained clinical remission with HSCT is initially likely to result from lymph ablation by drugs used in the conditioning regimen; altered immune reconstitution may be a later effect. Temporarily disrupting the immunological memory and ceasing the chronic inflammatory burden using non-ablative HSCT has been shown to be effective in non-controlled study designs \[[@CR9]\]. However, the recent ASTIC trial \[[@CR13]\] failed to demonstrate a statistically significant improvement in sustained disease remission at 1-year of HSCT. According to our study, the pooled rate of clinical remission was 73% (95% CI 36--93) for patients who underwent autologous HSCT, which was higher than 23% (95% CI 7--54) for patients who received ASC. Based on these trial findings, further study of HSCT in patients with refractory CD may be warranted.

When considering fistulizing CD, the existing pharmacological treatments for complex perianal fistulas have low efficacy in inducing fistula healing (antibiotics 21--48%; thiopurines 20--40%; anti-TNFs 23% complete responders) \[[@CR45]\]. In our study, the random-effects meta-analysis of all perianal CD studies showed that 57% (95% CI 44--69) of patients had healed fistula after local MSC injection, which is superior to all the above-mentioned treatments. The pooled OR for achieving fistula healing in patients who received SC injection versus control was 3.83 (95% CI 1.06--13.86, *P =* 0.04).

Whether SCT is associated with improved long-term outcomes for CD patients is unclear. Burt et al. \[[@CR9]\] reported that the percentage of clinical relapse-free survival after autologous nonmyeloablative HSCT was 91% at 1 year, 57% at 3 years, and 19% at 5 years. The percentage of patients in remission, steroid-free, or medication-free at any post-transplantation evaluation interval more than 5 years after HSCT remained at or greater than 70, 80, and 60%, respectively. Ciccocioppo et al. \[[@CR31]\] reported the efficacy of MSCs for refractory complex CD fistulae declined over time and fistula relapse-free survival was 50% at 2 years and 37% at 4 years. Cho et al. \[[@CR38]\] reported that 83.3% (20/24) of patients who received MSCs maintained complete fistula closure at 2 years. In the present meta-analysis, the pooled rate of clinical recurrence was 16% (95% CI 4--34) with a follow-up \>12 months. Studies assessing the long-term safety and efficacy of systemic MSC therapy for luminal CD are lacking. Further studies that investigate the impact of periodic MSC administration on long-term outcomes are necessary to establish SCT as maintenance therapy.

The safety of SCT remains a major concern that must be addressed before it can be officially approved for use for CD. During the first 12-month follow-up, viral infections were the most commonly observed complications of autologous HSCT \[[@CR46]\]. This is further confirmed by the ASTIC trial \[[@CR13]\], with most importantly proven or presumed infections associated with the pancytopenia induced by the conditioning regimen. In contrast, Kniazev et al. \[[@CR47]\] revealed no differences in the development of acute post-transfusion reactions, infectious complications, exacerbations of chronic inflammatory diseases, severe infectious complications, malignant transformation, and fatal cases in patients who received MSC therapy during 5-year follow-up. In our analysis, the pooled rate of SAEs and SAEs related to SCT were 12% (95% CI 6--23) and 8% (95% CI 3--18), respectively. When subgrouped by source of SCs, patients who received HSCs had a pooled rate of SAEs of 35% (95% CI 5--86), which is higher than with either BMSC (10%, 95% CI 2--42) or ASC (12%, 95% CI 7--18) infusion. MSCT does not require preparatory regimens involving high-dose chemotherapy and/or radiation; HSCT is thus associated with less procedure-related mortality. Overall, autologous HSCT for patients with refractory CD is feasible, but extraordinary supportive measures need to be implemented.

This meta-analysis also has limitations. First, assessment of the methodological quality determined that there were deficiencies in all the studies evaluated. Although only six RCTs \[[@CR13], [@CR17], [@CR27], [@CR37], [@CR39], [@CR42]\] met the inclusion criteria, the majority of studies included are phase I/IIa clinical trials. Second, clinical response exhibited statistical heterogeneity, which likely reflects the variability of definitions for clinical response, study design, sources of SCs, and time to clinical or endoscopic assessment. We used a random effects model to conservatively account for the clinical and statistical heterogeneity in the pooled studies. We also performed subgroup analyses to examine differences in the overall effect estimate.

Conclusions {#Sec20}
===========

So far, not enough studies have so far been performed to have a clear view about the use of SCT for CD; up to now the findings are encouraging but not conclusive. SCT seems potentially effective for refractory CD and has high efficacy in inducing fistula healing. Based on subgroup analysis, systemic allogeneic BMSC transfusion had relatively higher rates of inducing clinical response, while autologous ASC local injection had relatively higher rates of inducing fistula closure. Studies are needed to standardize MSC injection in often complex fistulas with multiple tracts to determine optimal dosing and source. Systemic infusion of SCs is not yet ready for the clinic and faces multiple challenges. Toxicity will remain the most significant barrier to HSCT in patients with CD.
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